Catalogue Number
BN-O1106
Analysis Method
Specification
98%(HPLC)
Storage
2-8°C
Molecular Weight
442.5
Appearance
Botanical Source
Structure Type
Category
SMILES
CCC1=C(C(=CC(=C1)CC2=CC(=C(C(=C2)C)N3C(=O)C=CC3=O)CC)C)N4C(=O)C=CC4=O
Synonyms
1,1'-[Methylenebis(2-ethyl-6-methyl-4,1-phenylene)]bis(1H-pyrrole-2,5-dione)/Bis(3-ethyl-5-Methyl-4-MaleiMidophenyl)Methane/1H-Pyrrole-2,5-dione, 1,1'-[methylenebis(2-ethyl-6-methyl-4,1-phenylene)]bis-/1-[4-[[4-(2,5-dioxopyrrol-1-yl)-3-ethyl-5-methylphenyl]methyl]-2-ethyl-6-methylphenyl]pyrrole-2,5-dione
IUPAC Name
1-[4-[[4-(2,5-dioxopyrrol-1-yl)-3-ethyl-5-methylphenyl]methyl]-2-ethyl-6-methylphenyl]pyrrole-2,5-dione
Density
1.3±0.1 g/cm3
Solubility
Flash Point
266.8±23.9 °C
Boiling Point
618.7±55.0 °C at 760 mmHg
Melting Point
165ºC
InChl
InChl Key
YNSSPVZNXLACMW-UHFFFAOYSA-N
WGK Germany
RID/ADR
HS Code Reference
Personal Projective Equipment
Correct Usage
For Reference Standard and R&D, Not for Human Use Directly.
Meta Tag
provides coniferyl ferulate(CAS#:105391-33-1) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
No Technical Documents Available For This Product.
31851691
Companies tend to publish financial reports in order to articulate strategies, disclose key performance measurements as well as summarise the complex relationships with external stakeholders as a result of their business activities. Therefore, any major changes to business models or key relationships will be naturally reflected within these documents, albeit in an unstructured manner. In this research, we automatically scan through a large and rich database, containing over 400,000 reports of companies in Japan, in order to generate structured sets of data that capture the essential features, interactions and resulting relationships among these firms. In doing so, we generate a citation type network where we empirically observe that node creation, annihilation and link rewiring to be the dominant processes driving its structure and formation. These processes prompt the network to rapidly evolve, with over a quarter of the interactions between firms being altered within every single calendar year. In order to confirm our empirical observations and to highlight and replicate the essential dynamics of each of the three processes separately, we borrow inspiration from ecosystems and evolutionary theory. Specifically, we construct a network evolutionary model where we adapt and incorporate the concept of fitness within our numerical analysis to be a proxy real measure of a company’s importance. By making use of parameters estimated from the real data, we find that our model reliably replicates degree distributions and motif formations of the citation network, and therefore reproducing both macro as well as micro, local level, structural features. This is done with the exception of the real frequency of bidirectional links, which are primarily formed as a result of an entirely separate and distinct process, namely the equity investments from one company into another.
Dynamics of essential interaction between firms on financial reports
Hayato Goto, Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing - original draft,1,2,* Eduardo Viegas, Conceptualization, Formal analysis, Investigation, Methodology, Validation, Writing - original draft,1 Hideki Takayasu, Investigation, Methodology, Supervision, Validation, Writing - review & editing,2,3 Misako Takayasu, Funding acquisition, Investigation, Supervision, Validation, Writing - review & editing,2 and Henrik Jeldtoft Jensen, Investigation, Project administration, Supervision, Validation, Writing - review & editing1,2 Yohsuke Murase, Editor
2019
24275849
CNS-active drugs are used relatively often during pregnancy. Use during early pregnancy may increase the risk of a congenital malformation; use during the later part of pregnancy may be associated with preterm birth, intrauterine growth disturbances and neonatal morbidity. There is also a possibility that drug exposure can affect brain development with long-term neuropsychological harm as a result. This paper summarizes the literature on such drugs used during pregnancy: opioids, anticonvulsants, drugs used for Parkinson’s disease, neuroleptics, sedatives and hypnotics, antidepressants, psychostimulants, and some other CNS-active drugs. In addition to an overview of the literature, data from the Swedish Medical Birth Register (1996-2011) are presented. The exposure data are either based on midwife interviews towards the end of the first trimester or on linkage with a prescribed drug register. An association between malformations and maternal use of anticonvulsants and notably valproic acid is well known from the literature and also demonstrated in the present study. Some other associations between drug exposure and outcome were found.
CNS active drugs, opioids, sedatives, hypnotics, antidepressants, psychostimulants, congenital malformations, neonatal morbidity
The Use of Central Nervous System Active Drugs During Pregnancy
Bengt Kallen,1,* Natalia Borg,2 and Margareta Reis3
2013 Oct;
20777727
OCCUPATIONAL DISEASES OF THE SKIN
John C. Bridge
1933 Aug 19;
Description :
Empty ...